Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (74 total)
-
Autor: Bayas, Antonios, Martina Menacher, Monika Christ, Lars Behrens, Andreas Rank, and Markus Naumann.
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-14
Descripción: Clinical Picture of Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination in a 55-year-old woman -
Autor: Muster, Viktoria, Thomas Gary, Reinhard B. Raggam, Albert WÖlfler, and Marianne Brodmann.
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-14
Descripción: Clinical Picture of a Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination in a 51-year-old woman -
Autor: Greinacher, Andreas, Thomas Thiele, Theodore E. Warkentin, Karin Weisser, Paul A. Kyrle, and Sabine Eichinger.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-09
Descripción: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1… -
Autor: Schultz, Nina H., Ingvild H. Sørvoll, Annika E. Michelsen, Ludvig A. Munthe, Fridtjof Lund-Johansen, Maria T. Ahlen, Markus Wiedmann, Anne-Hege Aamodt, Thor H. Skattør, Geir E. Tjønnfjord, and Pål A. Holme.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-09
Descripción: We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). -
Autor: the Siren Study Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-09
Descripción: Increased understanding of whether individuals who have recovered from COVID-19 are protected from future SARS-CoV-2 infection is an urgent requirement. We aimed to investigate whether antibodies against SARS-CoV-2 were associated with a decreased… -
Autor: the mRNA-1273 Study Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-06
Descripción: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19). -
Autor: Gupta, Aakriti, Mahesh V. Madhavan, Timothy J. Poterucha, Ersilia M. DeFilippis, Jessica A. Hennessey, Bjorn Redfors, Christina Eckhardt, Behnood Bikdeli, Jonathan Platt, Ani Nalbandian, Pierre Elias, Matthew J. Cummings, Shayan N. Nouri, Matthew…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-26
Descripción: The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have… -
Autor: the Oxford COVID-19 Vaccine Trial Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-03-30
Descripción: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. -
Autor: Joyner, Michael J., Rickey E. Carter, Jonathon W. Senefeld, Stephen A. Klassen, John R. Mills, Patrick W. Johnson, Elitza S. Theel, Chad C. Wiggins, Katelyn A. Bruno, Allan M. Klompas, Elizabeth R. Lesser, Katie L. Kunze, Matthew A. Sexton, Juan C.…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-03-18
Descripción: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be… -
Autor: Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani.
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-03-23
Descripción: Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
